The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
Abstract
Purpose: Patients with extensive-stage disease small-cell lung cancer (SCLC) have poor survival outcomes despite first-line chemotherapy with etoposide and platinum. This randomized, double-blind phase III study evaluated the efficacy and safety of ipilimumab or placebo plus etoposide and platinum in patients with newly diagnosed extensive-stage disease SCLC. Patients and Methods: Patients were randomly assigned at a ratio of one to one to receive chemotherapy with etoposide and platinum (cisplatin or carboplatin) plus ipilimumab 10 mg/kg or placebo every 3 weeks for a total of four doses each in a phased induction schedule (chemotherapy in cycles one to four; ipilimumab or placebo beginning in cycle three up to cycle six), followed by ipilimumab or placebo maintenance every 12 weeks. Primary end point was overall survival (OS) among patients receiving at least one dose of blinded study therapy. Results: Of 1,132 patients randomly assigned, 954 received at least one dose of study therapy (chemotherapy plus ipilimumab, n = 478; chemotherapy plus placebo, n = 476). Median OS was 11.0 months for chemotherapy plus ipilimumab versus 10.9 months for chemotherapy plus placebo (hazard ratio, 0.94; 95% CI, 0.81 to 1.09; P = .3775). Median progression-free survival was 4.6 months for chemotherapy plus ipilimumab versus 4.4 months for chemotherapy plus placebo (hazard ratio, 0.85; 95% CI, 0.75 to 0.97). Rates and severity of treatment-related adverse events were similar between arms, except for diarrhea, rash, and colitis, which were more frequent with chemotherapy plus ipilimumab. Rate of treatment-related discontinuation was higher with chemotherapy plus ipilimumab (18% v 2% with chemotherapy plus placebo). Five treatment-related deaths occurred with chemotherapy plus ipilimumab and two with chemotherapy plus placebo. Conclusion: Addition of ipilimumab to chemotherapy did not prolong OS versus chemotherapy alone in patients with newly diagnosed extensive-stage disease SCLC. No new or unexpected adverse events were observed with chemotherapy plus ipilimumab. Several ongoing studies are evaluating ipilimumab in combination with programmed death-1 inhibitors in SCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationNivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Cited by
First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J., Huemer, F., Losonczy, G., Johnson, M. L., Nishio, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809064 · Cited by 3,586
Self-citationCancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
Conforti, F., Pala, L., Bagnardi, V., De Pas, T., Martinetti, M., Viale, G., Gelber, R. D., & Goldhirsch, A. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30261-4 · Cited by 973
Goldman, J. W., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M. J., Özgüroğlu, M., Ji, J. H., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30539-8 · Cited by 688
Self-citationSmall-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
Dingemans, A.-M. C., Früh, M., Ardizzoni, A., Besse, B., Faivre-Finn, C., Hendriks, L. E., Lantuejoul, S., Peters, S., Reguart, N., Rudin, C. M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.207 · Cited by 626
Self-citationImmune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Sun, Q., Hong, Z., Zhang, C., Wang, L., Han, Z., & Ma, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01522-4 · Cited by 598
Xu, C., Chen, Y.-P., Du, X.-J., Liu, J.-Q., Huang, C.-L., Chen, L., Zhou, G.-Q., Li, W.-F., Mao, Y.-P., Hsu, C., et al. (2018) · BMJ · doi:10.1136/bmj.k4226 · Cited by 558
Ott, P. A., Elez, E., Hiret, S., Kim, D.-W., Morosky, A., Saraf, S., Piperdi, B., & Mehnert, J. M. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.5069 · Cited by 521
Unravelling the biology of SCLC: implications for therapy
Sabari, J. K., Lok, B. H., Laird, J. H., Poirier, J. T., & Rudin, C. M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.71 · Cited by 490
De Velasco, G., Je, Y., Bossé, D., Awad, M. M., Ott, P. A., Moreira, R. B., Schutz, F., Bellmunt, J., Sonpavde, G. P., Hodi, F. S., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0237 · Cited by 486
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Ganti, A. K. P., Loo, B. W., Bassetti, M., Blakely, C., Chiang, A., D'Amico, T. A., D'Avella, C., Dowlati, A., Downey, R. J., Edelman, M., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0058 · Cited by 486
Self-citationAntiemetics: ASCO Guideline Update
Hesketh, P. J., Kris, M. G., Basch, E., Bohlke, K., Barbour, S. Y., Clark-Snow, R. A., Danso, M. A., Dennis, K., Dupuis, L. L., Dusetzina, S. B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01296 · Cited by 470
Wang, J., Zhou, C., Yao, W., Wang, Q., Min, X., Chen, G., Xu, X., Li, X., Xu, F., Fang, Y., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00224-8 · Cited by 421
Emerging therapies for small cell lung cancer
Yang, S., Zhang, Z., & Wang, Q. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0736-3 · Cited by 407
Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells
Testa, U., Castelli, G., & Pelosi, E. (2018) · Cancers · doi:10.3390/cancers10080248 · Cited by 403
Govindan, R., Szczesna, A., Ahn, M.-J., Schneider, C.-P., Gonzalez Mella, P. F., Barlesi, F., Han, B., Ganea, D. E., Von Pawel, J., Vladimirov, V., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.7629 · Cited by 365
Self-citationDevelopment of Immunotherapy Combination Strategies in Cancer
Yap, T. A., Parkes, E. E., Peng, W., Moyers, J. T., Curran, M. A., & Tawbi, H. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1209 · Cited by 330
Liu, L., Bai, X., Wang, J., Tang, X.-R., Wu, D.-H., Du, S.-S., Du, X.-J., Zhang, Y.-W., Zhu, H.-B., Fang, Y., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0558 · Cited by 322
Immunotherapeutic approaches for small-cell lung cancer
Iams, W. T., Porter, J., & Horn, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0316-z · Cited by 311
Self-citationWallis, C. J. D., Butaney, M., Satkunasivam, R., Freedland, S. J., Patel, S. P., Hamid, O., Pal, S. K., & Klaassen, Z. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5904 · Cited by 290
Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors
Graus, F., & Dalmau, J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0194-4 · Cited by 276
Current standards for clinical management of small cell lung cancer
Farago, A. F., & Keane, F. K. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.01.16 · Cited by 265
Metadata
- Authors
- Reck, M., Luft, A., Szczesna, A., Havel, L., Kim, S.-W., Akerley, W., Pietanza, M. C., Wu, Y.-L., Zielinski, C., Thomas, M., Felip, E., Gold, K., Horn, L., Aerts, J., Nakagawa, K., Lorigan, P., Pieters, A., Kong Sanchez, T., Fairchild, J., & Spigel, D.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-11-01
- Volume
- 34
- Issue
- 31
- Pages
- 3740-3748
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2480201404
- Cited by
- 538
- References
- 44
- FWCI
- 25.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.